Nadia Tenenbaum

504 total citations
21 papers, 369 citations indexed

About

Nadia Tenenbaum is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, Nadia Tenenbaum has authored 21 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 7 papers in Molecular Biology and 6 papers in Psychiatry and Mental health. Recurrent topics in Nadia Tenenbaum's work include Multiple Sclerosis Research Studies (12 papers), Migraine and Headache Studies (6 papers) and Sphingolipid Metabolism and Signaling (6 papers). Nadia Tenenbaum is often cited by papers focused on Multiple Sclerosis Research Studies (12 papers), Migraine and Headache Studies (6 papers) and Sphingolipid Metabolism and Signaling (6 papers). Nadia Tenenbaum collaborates with scholars based in United States, Switzerland and Germany. Nadia Tenenbaum's co-authors include Ying Zhang, Ludwig Kappos, Jeffrey A. Cohen, Bruce Cree, Xiangyi Meng, Shihua Wen, Peggy Hours-Zesiger, Lesley Schofield, Uwe Reuter and Edward Fox and has published in prestigious journals such as Neurology, The Lancet Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Nadia Tenenbaum

21 papers receiving 366 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nadia Tenenbaum United States	11	234	122	90	80	51	21	369
Alaa Elmazny Egypt	11	128 0.5×	88 0.7×	79 0.9×	57 0.7×	20 0.4×	33	304
Andrzej Potemkowski Poland	9	163 0.7×	35 0.3×	85 0.9×	98 1.2×	31 0.6×	38	448
Jean‐Michel Pédespan France	9	104 0.4×	198 1.6×	89 1.0×	134 1.7×	35 0.7×	14	494
Wanda Castro-Borrero United States	8	227 1.0×	34 0.3×	61 0.7×	65 0.8×	48 0.9×	12	368
Johann te Water Naudé United Kingdom	8	160 0.7×	45 0.4×	119 1.3×	172 2.1×	19 0.4×	17	417
Mathias Granqvist Sweden	8	193 0.8×	36 0.3×	196 2.2×	100 1.3×	76 1.5×	13	503
Amer Awad United States	7	285 1.2×	27 0.2×	127 1.4×	45 0.6×	52 1.0×	14	430
Anna Jeong United States	12	51 0.2×	73 0.6×	112 1.2×	60 0.8×	34 0.7×	22	346
Constantinos Sfagos Greece	10	111 0.5×	30 0.2×	86 1.0×	60 0.8×	16 0.3×	17	309
Jorge Millán‐Pascual Spain	13	167 0.7×	42 0.3×	150 1.7×	62 0.8×	60 1.2×	28	394

Countries citing papers authored by Nadia Tenenbaum

Since Specialization

Citations

This map shows the geographic impact of Nadia Tenenbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadia Tenenbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadia Tenenbaum more than expected).

Fields of papers citing papers by Nadia Tenenbaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadia Tenenbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadia Tenenbaum. The network helps show where Nadia Tenenbaum may publish in the future.

Co-authorship network of co-authors of Nadia Tenenbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Nadia Tenenbaum. A scholar is included among the top collaborators of Nadia Tenenbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadia Tenenbaum. Nadia Tenenbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Montalbán, Xavier, Patrick Vermersch, Douglas L. Arnold, et al.. (2024). Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. The Lancet Neurology. 23(11). 1119–1132. 32 indexed citations

Overeem, Lucas Hendrik, Bianca Raffaelli, Robert Fleischmann, et al.. (2023). Serum tau protein elevation in migraine: a cross-sectional case–control study. The Journal of Headache and Pain. 24(1). 130–130. 8 indexed citations

Montalbán, Xavier, Patrick Vermersch, Douglas L. Arnold, et al.. (2023). Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2). Multiple Sclerosis and Related Disorders. 80. 105328–105328. 2 indexed citations

Lipton, Richard B., David W. Dodick, David Kudrow, et al.. (2021). Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies. Cephalalgia. 41(14). 1458–1466. 4 indexed citations

Reuter, Uwe, Peter J. Goadsby, Gabriel Paiva da Silva Lima, et al.. (2021). Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study. Journal of Neurology Neurosurgery & Psychiatry. 93(3). 254–262. 18 indexed citations

Goadsby, Peter J., Uwe Reuter, Michel Lantéri‐Minet, et al.. (2021). Long-term Efficacy and Safety of Erenumab. Neurology. 96(22). e2724–e2735. 33 indexed citations

Wang, Shuu‐Jiun, Artemio Roxas, Debashish Chowdhury, et al.. (2021). Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study. Cephalalgia. 41(13). 1285–1297. 42 indexed citations

Hunter, Samuel F., Florian P. Thomas, Mark Cascione, et al.. (2020). Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes✰. Multiple Sclerosis and Related Disorders. 45. 102346–102346. 1 indexed citations

Cree, Bruce, Myla Goldman, John R. Corboy, et al.. (2020). Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology. 78(1). 48–48. 34 indexed citations

10.

Dodick, David W., Stewart J. Tepper, Hans‐Christoph Diener, et al.. (2019). Efficacy of Erenumab in Chronic Migraine Patients with Medication Overuse and Prior Preventive Treatment Failure (S38.002). Neurology. 92(15_supplement). 2 indexed citations

11.

Cohen, Jeffrey A., et al.. (2019). Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Therapeutic Advances in Neurological Disorders. 12. 1278099892–1278099892. 57 indexed citations

12.

Tenenbaum, Nadia, et al.. (2018). A Long-term Experience with Fingolimod: Evaluation of Safety, Disability, and Treatment Satisfaction in Patients with Relapsing–Remitting Multiple Sclerosis (P6.377). Neurology. 90(15_supplement). 1 indexed citations

13.

Cascione, Mark, Nadia Tenenbaum, Jeanette Wendt, et al.. (2018). Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study. Multiple Sclerosis and Related Disorders. 25. 50–56. 10 indexed citations

14.

Cascione, Mark, Jeanette Wendt, Bruce Cree, et al.. (2017). PREFERMS study: post hoc analyses of patient retention, key clinical outcomes and patient satisfaction in an African-American patient subgroup (P6.382). Neurology. 88(16_supplement). 1 indexed citations

15.

Benedict, Ralph H. B., Douglas L. Arnold, Bruce Cree, et al.. (2017). Improved processing speed in multiple sclerosis during fingolimod therapy: oral Symbol Digit Modalities Test response in PREFERMS (P4.331). Neurology. 88(16_supplement). 1 indexed citations

16.

Crayton, Heidi, Brian Steingo, DeRen Huang, et al.. (2016). Real-World Patient Retention and Satisfaction on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis; Results from PREFERMS (P6.167). Neurology. 86(16_supplement). 1 indexed citations

17.

Cree, Bruce, Daniel Wynn, Mark Cascione, et al.. (2016). Key Results from PREFERMS: Real-World Patient Retention and Outcomes on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis (P3.115). Neurology. 86(16_supplement). 5 indexed citations

18.

Calkwood, Jonathan, Bruce Cree, Heidi Crayton, et al.. (2014). Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial. BMC Neurology. 14(1). 220–220. 32 indexed citations

19.

Romero‐Martínez, Ángel, Jorge Correale, Patricia K. Coyle, Xiangyi Meng, & Nadia Tenenbaum. (2014). Efficacy and Safety of Fingolimod in Hispanic Patients with Multiple Sclerosis: Pooled Clinical Trial Analyses. Advances in Therapy. 31(10). 1072–1081. 14 indexed citations

20.

Emre, Murat, Werner Poewe, Peter Paul De Deyn, et al.. (2014). Long-term Safety of Rivastigmine in Parkinson Disease Dementia. Clinical Neuropharmacology. 37(1). 9–16. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact